A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor, KRAS Mutation
Interventions
DRUG

BI 3706674

BI 3706674

Trial Locations (17)

100

National Taiwan University Hospital, Taipei

704

NCKUH, Tainan City

10065

Memorial Sloan-Kettering Cancer Center, New York

13620

Seoul National University Bundang Hospital, Seongnam

16499

Ajou University Hospital, Suwon

19104

University of Pennsylvania, Philadelphia

77030

The University of Texas MD Anderson Cancer Center, Houston

85054

Mayo Clinic-Arizona, Phoenix

06511

Yale Cancer Center, New Haven

02114

Massachusetts General Hospital, Boston

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

135-8550

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

135-710

Samsung Medical Center, Seoul

137-701

The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06056024 - A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus | Biotech Hunter | Biotech Hunter